In patients with venous thromboembolism (VTE) who are candidates for oral anticoagulation, apixaban results in fewer ...

Although the Trump administration's healthcare policies pose risks for Bristol-Myers Squibb, the chaos opens a contrarian door for BMY stock.

Bristol-Myers Squibb Co. prevailed against investor allegations it misled them about a payout tied to Food and Drug ...

Among the safety stocks discussed by Cramer during the episode on May 14, Bristol-Myers Squibb Company (NYSE:BMY) was first ...

Talent platform Eightfold rolled out two transformative agentic AI tools at its recent summit: AI Interviewer Agent and ...

Bristol Myers Squibb is calling on the world to chip in more for drug costs to support U.S. research and development. CEO ...

Treatment-resistant schizophrenia is a disabling illness, affecting approximately 8 million people worldwide with profound ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Treatment of optic neuritis with corticosteroids, findings from the Optic Neuritis Treatment Trial and the validity of ...

First-line treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) significantly improved survival compared with lenvatinib ...

If President Trump's threat to impose tariffs on pharmaceutical products goes through, it would have severe consequences for ...

Bristol Myers CEO Christopher Boerner advocates global cost-sharing for drug R&D and criticizes PBMs. Read nore here.